Nephrotic Syndrome after Infliximab Treatment in a Patient with Ulcerative Colitis

被引：0

作者：

Dumitrescu, Gabriela ^{[1
,2
]}

Dahan, Karine ^{[3
]}

Treton, Xavier ^{[1
]}

Corcos, Olivier ^{[1
]}

Bouhnik, Yoram ^{[1
]}

Stefanescu, Carmen ^{[1
]}

机构：

[1] Univ Paris 07, Beaujon Hosp, Dept Gastroenterol IBD & Nutr Support, Clichy, France

[2] Gr T Popa Univ Med & Pharm Iasi, Iasi, Romania

[3] Univ Paris 06, Tenon Hosp, Dept Nephrol, Paris, France

来源：

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES | 2015年 / 24卷 / 02期

关键词：

ulcerative colitis; infliximab; nephrotic syndrome; ANTI-TNF-ALPHA; CROHNS-DISEASE; SECONDARY AMYLOIDOSIS; SYSTEMIC AMYLOIDOSIS; RHEUMATOID-ARTHRITIS; THERAPY; RITUXIMAB; NEPHRITIS;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Tumor necrosis factor (TNF)-targeted therapies are increasingly used to treat a variety of inflammatory and autoimmune diseases. They are now used worldwide, and this class of medication has revolutionized the treatment of these diseases and the quality of life for patients but it also poses risk of developing various side effects including infections, exacerbation of some neurological manifestations, cutaneous lesions or induces antibody production. Renal complications are uncommon and poorly recognized. This report describes a probable case of infliximab-induced focal segmental glomerulosclerosis clinically presented as a severe nephrotic syndrome in a patient with ulcerative colitis.

引用

页码：249 / 251

页数：3

共 17 条

[1] Secondary amyloidosis in Crohn's disease:: treatment with tumour necrosis factor inhibitor [J].

Boscá, MM ;

Pérez-Baylach, CM ;

Solis, MA ;

Antón, R ;

Mayordomo, E ;

Pons, S ;

Mínguez, M ;

Benages, A .

GUT, 2006, 55 (02) :294-295

[2] Infliximab in the treatment of amyloidosis secondary to Crohn's disease [J].

Cabezuelo, Juan B. ;

Egea, Juan P. ;

Ramos, Fernanda ;

Torrella, Emilio ;

Muray, Salome ;

Alcazar, Concepcion .

NEFROLOGIA, 2012, 32 (03) :385-388

[3] Infliximab and nephrotic syndrome [J].

Chin, G ;

Luxton, G ;

Harvey, JM .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (12) :2824-2826

[4]

den Broeder AA, 2003, NETH J MED, V61, P137

[5] Secondary Amyloidosis in a Patient with Long Duration Crohn's Disease Treated with Infliximab [J].

Fidalgo, Catarina ;

Calado, Joaquim ;

Cravo, Marilia .

BIODRUGS, 2010, 24 :15-17

[6] Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease [J].

Iizuka, M ;

Konno, S ;

Horie, Y ;

Itou, H ;

Shindo, K ;

Watanabe, S .

GUT, 2006, 55 (05) :744-745

[7]

Iizuka Masahiro, 2011, Inflamm Bowel Dis, V17, pE67, DOI 10.1002/ibd.21720

[8] Drug-Induced Granulomatous Interstitial Nephritis in a Patient With Ankylosing Spondylitis During Therapy With Adalimumab [J].

Korsten, Peter ;

Sweiss, Nadera J. ;

Nagorsnik, Ulf ;

Niewold, Timothy B. ;

Groene, Hermann-Josef ;

Gross, Oliver ;

Mueller, Gerhard A. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 56 (06) :E17-E21

[9] Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis [J].

Leiper, Keith ;

Martin, Kate ;

Ellis, Anthony ;

Subramanian, Sreedhar ;

Watson, Alastair J. ;

Christmas, Steve E. ;

Howarth, Deborah ;

Campbell, Fiona ;

Rhodes, Jonathan M. .

GUT, 2011, 60 (11) :1520-1526

[10] Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease [J].

Munyentwali, Helene ;

Bouachi, Khedidja ;

Audard, Vincent ;

Remy, Philippe ;

Lang, Philippe ;

Mojaat, Rachid ;

Deschenes, Georges ;

Ronco, Pierre M. ;

Plaisier, Emmanuelle M. ;

Dahan, Karine Y. .

KIDNEY INTERNATIONAL, 2013, 83 (03) :511-516

← 1 2 →